Bausch & Lomb Corp (BLCO) Form 8-K — Oct 28, 2026
Bausch + Lomb reported strong Q3 2026 results on October 28, 2026, with revenue of $1.375 billion, up 7% reported and 8% on a constant currency basis versus Q3 2025. GAAP net income swung to $32 million from a $28 million loss a year ago, a $60 million favorable change, and adjusted EBITDA rose to $325 million from $243 million. Growth was broad-based across all three segments, led by Pharmaceuticals (+11%), with MIEBO revenue up 42% to $119 million and the premium IOL portfolio up roughly 70%. The company raised its full-year 2026 guidance, lifting revenue to $5.450B-$5.550B and adjusted EBITDA excluding acquired IPR&D to $1.090B-$1.140B.
Key figures
- Eps
- 0.09
- Revenue
- 1375000000
- Guidance
- FY2026 revenue raised to $5.450B-$5.550B (6.1-8.0% constant currency growth); adjusted EBITDA excluding acquired IPR&D raised to $1.090B-$1.140B
- Net Income
- 32000000
- Revenue Yoy
- 7% reported / 8% constant currency
- Cash Position
- 515000000
- Miebo growth
- 42%
- Lumify growth
- 35%
- Miebo revenue
- 119000000
- Adjusted eps q3
- 0.34
- Daily sihy growth
- 24%
- Adjusted ebitda q3
- 325000000
- Nine month revenue
- 4013000000
- Premium iol growth
- ~70%
- Operating income q3
- 155000000
- Adjusted net income q3
- 123000000
- Operating cash flow q3
- 233000000
- Segment revenue surgical
- 234000000
- Adjusted ebitda prior year
- 243000000
- Segment revenue vision care
- 774000000
- Segment revenue pharmaceuticals
- 367000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.